Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.46-8.89%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ELDN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advancement of drug candidates in autoimmune and ALS trials | Eledon is a clinical-stage biotech focused on autoimmune and ALS drugs. | Intact | Trial failures or halted studies | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not an established earnings compounder. The long-term thesis remains in a watch state, with low confidence and high risk.
The evidence snapshot gives no valuation measure or direct account of market expectations, so whether ELDN is cheap or expensive versus peers is unclear. The market appears to be weighing uncertain clinical progress and ongoing cash use, but the evidence does not show how much success is already assumed.
Near term, results have been uneven, with an earnings miss in May and an in-line report in August; recent performance remains below the industry cohort. Management says the Phase 3 kidney-transplantation trial is on track to start in late 2026, while cash fell to $88.8 million in the second quarter and is expected to fund operations into the second quarter of 2027.
The multi-year thesis hinges on starting the Phase 3 trial on schedule and showing further progress in islet cell transplantation. Near term, a guidance cut or further weakening in jobs data could add pressure; continued strong results and guidance from sector bellwethers could support sector momentum, but would not resolve ELDN's company-specific risks.
Over the next 1 to 3 years, ELDN's setup depends on clinical execution and whether its remaining funds can support operations through key development steps. The evidence is limited, and the loss-making business and high risk leave the thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Eledon Pharmaceuticals, Inc.'s published investment case. The stated target is EPS loss improves from -0.87 in FY26 to better than -0.72 in FY27. |
| Broken |
| EPS loss worsens or stays below -0.87 in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Cash funds operations into 2Q 2027 | It has cash to fund operations into 2Q 2027. | Intact | Cash runs out before 2Q 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.80 → $-0.83 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-25 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-26 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-27 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-28 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-29 | $-0.80 | Unavailable | 2 / 0 |
| 2026-07-30 | $-0.72 | $0 | 3 / 4 |
| 2026-07-31 | $-0.72 | $0 | 3 / 4 |
| 2026-08-01 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-02 | $-0.72 | $0 | 3 / 4 |
| 2026-08-03 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-04 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-05 | $-0.72 | $0 | 3 / 4 |
| 2026-08-06 | $-0.72 | $0 | 3 / 4 |
| 2026-08-07 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-08 | $-0.72 | $0 | 3 / 4 |
| 2026-08-09 | $-0.72 | $0 | 3 / 4 |
| 2026-08-10 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-11 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-12 | $-0.72 | $0 | 3 / 4 |
| 2026-08-13 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-14 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-15 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-16 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-17 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-18 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-19 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-20 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-21 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-22 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-23 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-24 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-25 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-26 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-27 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-28 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-29 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-30 | $-0.80 | Unavailable | 2 / 0 |
| 2026-08-31 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-01 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-02 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-03 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-04 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-05 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-06 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-07 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-08 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-09 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-10 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-11 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-12 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-13 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-14 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-15 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-16 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-17 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-18 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-19 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-20 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-21 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-22 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-23 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-24 | $-0.80 | Unavailable | 2 / 0 |
| 2026-09-25 | $-0.83 | Unavailable | 2 / 0 |
| 2026-09-26 | $-0.83 | Unavailable | 2 / 0 |
| 2026-09-27 | $-0.83 | Unavailable | 2 / 0 |
| 2026-09-28 | $-0.83 | Unavailable | 2 / 0 |
| 2026-09-29 | $-0.83 | Unavailable | 2 / 0 |
| 2026-09-30 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-01 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-02 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-03 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-04 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-05 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-06 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-07 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-08 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-09 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-10 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-11 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-12 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-13 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-14 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-15 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-16 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-17 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-18 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-19 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-20 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-21 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-22 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-23 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-24 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-25 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-26 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-27 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-28 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-29 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-30 | $-0.83 | Unavailable | 2 / 0 |
| 2026-10-31 | $-0.83 | Unavailable | 2 / 0 |
| 2026-11-01 | $-0.83 | Unavailable | 2 / 0 |
| 2026-11-02 | $-0.83 | Unavailable | 2 / 0 |
| 2026-11-03 | $-0.83 | Unavailable | 2 / 0 |
| 2026-11-04 | $-0.83 | Unavailable | 2 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.